The investigation was prompted when cough syrup (containing narcotic substance) worth Rs 57.6 crore on its way to Bangladesh was intercepted in Shillong six months ago, according to a statement issued by state Drug Control Administration (DCA).
"The company, M/s Abott Health Care Pvt Ltd, supplied the stocks of Phensedyl from Baddi plant to its C&F Depot at Uppal. The depot invoiced the stocks to specific distributors recruited by the state marketing managers and their subordinates. These 'retailers' were billed large quantities of the stock. Investigation reveals that most of these 'retailers' don't exist, the statement said.
When contacted the company, a spokesperson denied the drug maker's involvement in the alleged diversion.
"As a global health-care company (Abbott) is committed to maintaining highly reputable professional ethics and standards worldwide. Our policies and procedures require strict compliance with all local laws and regulations.
Also Read
Director DCA Akun Sabarwal told PTI that they have sent a questionnaire to the company seeking details and the answers were found to be "inconsistent" with the agency's investigation.
The CID registered a case under sections 8, 21, 22 and 29 of the Narcotic Drugs and Psychotropic Substances Act, Act and sections 468 (forgery for the purpose of cheating) and 471 (using as genuine a forged document) of IPC.